Avelumab — Drug Intelligence | 31 EU Trials

Filter these 31 trials by condition, phase, country and more.

Open in Search →

31 Registered trials

15 Recruiting

12 Completed trials

27 Sponsors

18 Countries

Phase III

Phase II

Phase I/II

Phase III: 5 Phase II/III: 1 Phase II: 19 Phase I/II: 3 Phase III/IV: 1 Phase IV: 1 Phase I (Other): 1

Oversight events:

3 temporary halts 1 urgent safety measure 2 unexpected events 1 corrective measure across 4 trials

View oversight register →

Indications tested

Triple negative breast cancer 2 Head and neck cancer 2 Transitional cell carcinoma 2 Squamous cell carcinoma of head and neck 1 Anal cancer 1 Hepatocellular carcinoma 1 Penile cancer 1 Head and neck cancer metastatic 1 Oesophageal squamous cell carcinoma 1 Bladder cancer 1 Neuroendocrine carcinoma 1

Sponsors using this IMP

Bicycletx Limited 2 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 2 Groupe Oncologie Radiotherapie Tete Cou 2 Merck Healthcare KGaA 2 Centre Hospitalier Regional De Marseille 1 Centre Hospitalier Universitaire Rouen 1 Charite Universitaetsmedizin Berlin KöR 1 Fondation Franc.Cancerologie Digestive 1 Fondazione GONO Plus 1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica 1

All trials

31 total

Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Not authorised

2023-504231-41-00 Phase II/III 1 country Bicycletx Limited
Avelumab Short Maintenance Trial Pending

2024-512975-11-01 Phase III/IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence Pending

2024-515825-27-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial – GOIRC-02-2025 Pending

2025-524077-16-00 Phase II 1 country G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Phase II 18 countries Bicycletx Limited
CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) P… Recruiting

2024-516328-32-00 Phase II 1 country Centre Hospitalier De Versailles
Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma… Recruiting

2023-510559-41-00 Phase II 1 country Groupe Oncologie Radiotherapie Tete Cou
PULSE : Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including a platinum salt in patie… Recruiting

2024-514997-27-00 Phase II 1 country Centre Hospitalier Regional Universitaire
A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and… Recruiting

2025-521738-27-00 Phase II 1 country Charite Universitaetsmedizin Berlin KöR
DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for … Recruiting

2025-521644-37-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type… Recruiting

2024-519481-44-00 Phase II 1 country Gruppo Oncologico Dell'Italia Meridionale
PROSPECTIVE EVALUATION OF THE DDR GENES ALTERATION TO PREDICT RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL CANCER Recruiting

2024-516450-21-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therap… Recruiting

2024-512053-24-00 Phase II 1 country Fondazione GONO Plus
Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Mo… Recruiting

2024-516777-77-00 Phase II 1 country Vall D Hebron Institute Of Oncology
CHASIT Recruiting

2024-516940-24-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Immunological variables associated to ICI toxicity in cancer patients Recruiting

2023-505360-11-00 Phase II 1 country Institut Jules Bordet
ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling Recruiting

2023-510527-29-00 Phase II 1 country Rigshospitalet
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting

2023-508302-24-00 Phase II 5 countries Gilead Sciences Inc.
AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting

2024-514791-40-00 Phase I/II 5 countries Institut Gustave Roussy
DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothel… Ended

2024-518244-20-01 Phase II 2 countries Queen Mary University Of London
Master Protocol for Avelumab Continuation Study. Ended

2023-509466-38-00 Phase III 7 countries Pfizer Inc.
Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca… Ended

2024-513707-14-00 Phase III 1 country Unicancer
Avelumab Program Rollover Study Ended

2024-514274-46-00 Phase III 7 countries Merck KGaA
REGOMUNE : A phase I/II study of Regorafenib plus Avelumab in solid tumors Ended

2023-509500-15-00 Phase I/II 1 country Institut Bergonie

Showing 1–24 of 31 trials

← All drugs A–Z